Page 43 - GPD-1-1

Gene & Protein in Disease Genetically engineered T cells in cancer immunotherapy

in vitro. Cancer Sci, 111(11): 4051–4060. 62. Mei H, Li C, Jiang H, et al., 2021, A bispecific CAR-T cell
therapy targeting BCMA and CD38 in relapsed or refractory
https://doi.org/10.1111/cas.14638
multiple myeloma. J Hematol Oncol, 14(1): 161.
52. Liu M, Deng H, Mu J, et al., 2021, Ibrutinib improves the
efficacy of anti-CD19-CAR T-cell therapy in patients with https://doi.org/10.1186/s13045-021-01170-7
refractory non-Hodgkin lymphoma. Cancer Sci, 112(7): 63. Hegde M, Mukherjee M, Grada Z, et al., 2021, Tandem CAR
2642–2651. T cells targeting HER2 and IL13Ralpha2 mitigate tumor
https://doi.org/10.1111/cas.14915 antigen escape. J Clin Invest, 131(13): e152477.
53. Prinzing B, Zebley CC, Petersen CT, et al., 2021, Deleting https://doi.org/10.1172/JCI152477
DNMT3A in CAR T cells prevents exhaustion and enhances 64. Zhao J, Lin Q, Song Y, et al., 2018, Universal CARs, universal
antitumor activity. Sci Transl Med, 13(620): eabh0272. T cells, and universal CAR T cells. J Hematol Oncol,
https://doi.org/10.1126/scitranslmed.abh0272 11(1): 132.
54. Wang Y, Tong C, Dai H, et al., 2021, Low-dose decitabine https://doi.org/10.1186/s13045-018-0677-2
priming endows CAR T cells with enhanced and persistent 65. Tang TCY, Xu N, Nordon R, et al., 2022, Donor T cells for
antitumour potential via epigenetic reprogramming. Nat CAR T cell therapy. Biomark Res, 10(1): 14.
Commun, 12(1): 409.
https://doi.org/10.1186/s40364-022-00359-3
https://doi.org/10.1038/s41467-020-20696-x
66. Lin H, Cheng J, Mu W, et al., 2021, Advances in universal
55. Lynn RC, Weber EW, Sotillo E, et al., 2019, c-Jun CAR-T cell therapy. Front Immunol, 12: 744823.
overexpression in CAR T cells induces exhaustion resistance.
Nature, 576(7786): 293–300. https://doi.org/10.3389/fimmu.2021.744823
https://doi.org/10.1038/s41586-019-1805-z 67. Torikai H, Reik A, Liu PQ, et al., 2012, A foundation for
universal T-cell based immunotherapy: T cells engineered
56. Seo H, Gonzalez-Avalos E, Zhang W, et al., 2021, BATF and to express a CD19-specific chimeric-antigen-receptor and
IRF4 cooperate to counter exhaustion in tumor-infiltrating eliminate expression of endogenous TCR. Blood, 119(24):
CAR T cells. Nat Immunol, 22(8): 983–995. 5697–5705.
https://doi.org/10.1038/s41590-021-00964-8 https://doi.org/10.1182/blood-2012-01-405365
57. Tong C, Zhang Y, Liu Y, et al., 2020, Optimized tandem 68. Qasim W, Zhan H, Samarasinghe S, et al., 2017, Erratum
CD19/CD20 CAR-engineered T cells in refractory/relapsed for the report: Molecular remission of infant B-ALL after
B-cell lymphoma. Blood, 136(14): 1632–1644. infusion of universal TALEN gene-edited CAR T cells. Sci
https://doi.org/10.1182/blood.2020005278 Transl Med, 9: aam9292.
58. Wei G, Zhang Y, Zhao H, et al., 2021, CD19/CD22 dual- https://doi.org/10.1126/scitranslmed.aam9292
targeted CAR T-cell therapy for relapsed/refractory 69. Hu Y, Zhou Y, Zhang M, et al., 2021, CRISPR/Cas9-
aggressive B-cell lymphoma: A safety and efficacy study. engineered universal CD19/CD22 dual-targeted CAR-T cell
Cancer Immunol Res, 9(9): 1061–1070. therapy for relapsed/refractory B-cell acute lymphoblastic
https://doi.org/10.1158 / 2326-6066.CIR-20-0675 leukemia. Clin Cancer Res, 27(10): 2764–2772.
59. Cordoba S, Onuoha S, Thomas S, et al., 2021, CAR T cells https://doi.org/10.1158 / 1078-0432.CCR-20-3863
with dual targeting of CD19 and CD22 in pediatric and 70. Benjamin R, Graham C, Yallop D, et al., 2020, Genome-
young adult patients with relapsed or refractory B cell acute edited, donor-derived allogeneic anti-CD19 chimeric
lymphoblastic leukemia: A phase 1 trial. Nat Med, 27(10): antigen receptor T cells in paediatric and adult B-cell acute
1797–1805. lymphoblastic leukaemia: results of two phase 1 studies.
https://doi.org/10.1038/s41591-021-01497-1 Lancet, 396(10266): 1885–1894.
60. Tu S, Zhou X, Guo Z, et al., 2019, CD19 and CD70 dual-target https://doi.org/10.1016/S0140-6736(20)32334-5
chimeric antigen receptor T-cell therapy for the treatment 71. Rafiq S, Hackett CS, Brentjens RJ, 2020, Engineering
of relapsed and refractory primary central nervous system strategies to overcome the current roadblocks in CAR T cell
diffuse large B-cell lymphoma. Front Oncol, 9: 1350. therapy. Nat Rev Clin Oncol, 17(3): 147–167.
https://doi.org/10.3389/fonc.2019.01350 https://doi.org/10.1038/s41571-019-0297-y
61. Kang L, Zhang J, Li M, et al., 2020, Characterization of novel 72. Shi D, Shi Y, Kaseb AO, et al., 2020, Chimeric antigen
dual tandem CD19/BCMA chimeric antigen receptor T cells receptor-glypican-3 T-cell therapy for advanced
to potentially treat multiple myeloma. Biomark Res, 8: 14.
hepatocellular carcinoma: Results of phase I trials. Clin
https://doi.org/10.1186/s40364-020-00192-6 Cancer Res, 26(15): 3979–3989.

Volume 1 Issue 1 (2022) 12 https://doi.org/10.36922/gpd.v1i1.114